Transforming transplant.
One lung at a time.
Driven by data and powered by the expertise of our clinical teams, our integrated EVLP service simplifies the journey from organ offer to transplant with the ultimate goal that no transplantable lung goes unused.
With the support of our parent company, public benefit corporation United Therapeutics, we are dedicated to achieving this vision. We work tirelessly to transform the paradigm of transplant to ultimately increase the number of organs available.
As a leading provider of EVLP services, our model is designed to reduce the resource burden of transplantation from beginning to end. We provide seamless EVLP services to transplant centers, and ultimately aim to increase organ utilization together. One lung at a time.
Patient centric.
Just like our founders.
Lung Bioengineering's patient-centric approach is ingrained in our DNA. Just like our parent company,
we are dedicated to addressing the unmet needs of our patients and delivering value to the wider communities in which we are based.
EVLP is just one of the many solutions we offer in our collective mission to help patients suffering from end-stage organ disease.
Founded in1996
Founded in1996
UNITED THERAPEUTICS
Parent Company
United Therapeutics Corporation was founded in 1996 by Martine Rothblatt following the diagnosis of her daughter with pulmonary arterial hypertension (PAH). A biotech company born out of exceptional circumstances, since its inception, United Therapeutics has successfully launched and marketed several FDA-approved therapies for cardiopulmonary diseases and pediatric cancer. Since 2011, United Therapeutics has been at the forefront of transforming transplantation through novel programs to address the acute national shortage of transplantable organs. In 2021, United Therapeutics became the first publicly traded biotech or pharmaceutical company to take the form of a public benefit corporation, deepening its commitment to patients with end-stage organ disease. Its public benefit purpose is to provide a brighter future for patients by developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.
UTC Pipeline
UTC's next-generation therapies are designed to address the unmet needs of patients living with conditions such as PAH, PH-ILD, and end-stage organ disease. Click below to view the United Therapeutics pipeline.
UTC PipelineFounded in2014
Founded in2014
LUNG BIOENGINEERING INC
Lung Bioengineering Inc. owns and operates the first and only full-service EVLP centers in the United States. The company was formed as a subsidiary of United Therapeutics in 2014 to be a leading provider of EVLP services. Our EVLP centers are driven by data and powered 24/7, 365 days a year, by the expertise of our LBE Clinical Specialists. Our integrated EVLP service aims to reduce resource burdens from donation to transplant and increase organ utilization. Lung Bioengineering’s vision is a world where no one waits for a lifesaving transplant to become a reality. We are dedicated to achieving this vision one organ at a time.
Hear about EVLP from our director
Brandi Zofkie, Associate Vice President of Lung Bioengineering, discusses our ex vivo lung perfusion system and the personal passion that fueled founder Martine Rothblatt.
Click to ListenThe information contained in the linked multimedia content represents the views and opinions of the participants and does not necessarily represent the views and opinions of Lung Bioengineering or its parent companies. Reference to any individual experience shared in this podcast is not intended to infer or represent a typical result as individual results may vary.
Ready to start your journey with us?
Become a LBE partner